Upstream Bio Q2 FY26 net loss narrows 0.66% to $39.7 million

• Upstream Bio posted a net loss of $39.7 million, narrowing from $40 million a year earlier.
• Research and development expense slipped 4.75% to $36.1 million, while general and administrative costs eased 4.04% to $7.1 million.
• Cash, cash equivalents and short-term investments totaled $261.3 million as of June 30, expected to fund operations through 2027.
• Enrollment finished in the Phase 2 VENTURE COPD trial with 481 participants; data are expected in the second half of 2027.
• Management reiterated plans to start Phase 3 trials of verekitug in severe asthma and CRSwNP in Q1 2027, with FDA End-of-Phase 2 interactions on track.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608110700PRIMZONEFULLFEED9807452) on August 11, 2026, and is solely responsible for the information contained therein.